299 related articles for article (PubMed ID: 15492926)
21. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations.
Gervasini G; Vizcaino S; Gasiba C; Carrillo JA; Benitez J
Ther Drug Monit; 2005 Dec; 27(6):819-21. PubMed ID: 16306861
[TBL] [Abstract][Full Text] [Related]
22. Analysis of pharmacogenetic traits in two distinct South African populations.
Ikediobi O; Aouizerat B; Xiao Y; Gandhi M; Gebhardt S; Warnich L
Hum Genomics; 2011 May; 5(4):265-82. PubMed ID: 21712189
[TBL] [Abstract][Full Text] [Related]
23. Genetic variability, haplotype structures, and ethnic diversity of hepatic transporters MDR3 (ABCB4) and bile salt export pump (ABCB11).
Lang T; Haberl M; Jung D; Drescher A; Schlagenhaufer R; Keil A; Mornhinweg E; Stieger B; Kullak-Ublick GA; Kerb R
Drug Metab Dispos; 2006 Sep; 34(9):1582-99. PubMed ID: 16763017
[TBL] [Abstract][Full Text] [Related]
24. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Lepper ER; Baker SD; Permenter M; Ries N; van Schaik RH; Schenk PW; Price DK; Ahn D; Smith NF; Cusatis G; Ingersoll RG; Bates SE; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
Clin Cancer Res; 2005 Oct; 11(20):7398-404. PubMed ID: 16243813
[TBL] [Abstract][Full Text] [Related]
25. Similarity in recombination rate and linkage disequilibrium at CYP2C and CYP2D cytochrome P450 gene regions among Europeans indicates signs of selection and no advantage of using tagSNPs in population isolates.
Pimenoff VN; Laval G; Comas D; Palo JU; Gut I; Cann H; Excoffier L; Sajantila A
Pharmacogenet Genomics; 2012 Dec; 22(12):846-57. PubMed ID: 23089684
[TBL] [Abstract][Full Text] [Related]
26. Patterns of genetic variation in the hypertension candidate gene GRK4: ethnic variation and haplotype structure.
Lohmueller KE; Wong LJ; Mauney MM; Jiang L; Felder RA; Jose PA; Williams SM
Ann Hum Genet; 2006 Jan; 70(Pt 1):27-41. PubMed ID: 16441255
[TBL] [Abstract][Full Text] [Related]
27. Genetic diversity of CYP3A4 and CYP3A5 polymorphisms in North African populations from Morocco and Tunisia.
Novillo A; Romero-Lorca A; Gaibar M; Bahri R; Harich N; Sánchez-Cuenca D; Esteban E; Fernández-Santander A
Int J Biol Markers; 2015 Feb; 30(1):e148-51. PubMed ID: 25385241
[TBL] [Abstract][Full Text] [Related]
28. Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups.
Li D; Zhang GL; Lou YQ; Li Q; Wang X; Bu XY
J Clin Pharm Ther; 2007 Feb; 32(1):89-95. PubMed ID: 17286792
[TBL] [Abstract][Full Text] [Related]
29. Factors influencing midazolam hydroxylation activity in human liver microsomes.
He P; Court MH; Greenblatt DJ; von Moltke LL
Drug Metab Dispos; 2006 Jul; 34(7):1198-207. PubMed ID: 16638818
[TBL] [Abstract][Full Text] [Related]
30. Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers.
Rodríguez-Antona C; Jande M; Rane A; Ingelman-Sundberg M
Clin Pharmacol Ther; 2005 Apr; 77(4):259-70. PubMed ID: 15903124
[TBL] [Abstract][Full Text] [Related]
31. CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations.
Balram C; Zhou Q; Cheung YB; Lee EJ
Eur J Clin Pharmacol; 2003 Jun; 59(2):123-6. PubMed ID: 12756511
[TBL] [Abstract][Full Text] [Related]
32. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population.
Mirghani RA; Sayi J; Aklillu E; Allqvist A; Jande M; Wennerholm A; Eriksen J; Herben VM; Jones BC; Gustafsson LL; Bertilsson L
Pharmacogenet Genomics; 2006 Sep; 16(9):637-45. PubMed ID: 16906018
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-8 genetic diversity, haplotype structure and production differ in two ethnically distinct South African populations.
Paximadis M; Picton ACP; Sengupta D; Ramsay M; Puren A; Tiemessen CT
Cytokine; 2021 Jul; 143():155489. PubMed ID: 33814271
[TBL] [Abstract][Full Text] [Related]
34. The analysis of APOL1 genetic variation and haplotype diversity provided by 1000 Genomes project.
Peng T; Wang L; Li G
BMC Nephrol; 2017 Aug; 18(1):267. PubMed ID: 28800731
[TBL] [Abstract][Full Text] [Related]
35. Interpopulation variation frequency of human inosine 5'-monophosphate dehydrogenase type II (IMPDH2) genetic polymorphisms.
Mohamed MF; Frye RF; Langaee TY
Genet Test; 2008 Dec; 12(4):513-6. PubMed ID: 18976158
[TBL] [Abstract][Full Text] [Related]
36. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
Op den Buijsch RA; Christiaans MH; Stolk LM; de Vries JE; Cheung CY; Undre NA; van Hooff JP; van Dieijen-Visser MP; Bekers O
Fundam Clin Pharmacol; 2007 Aug; 21(4):427-35. PubMed ID: 17635182
[TBL] [Abstract][Full Text] [Related]
37. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population.
Fukushima-Uesaka H; Saito Y; Watanabe H; Shiseki K; Saeki M; Nakamura T; Kurose K; Sai K; Komamura K; Ueno K; Kamakura S; Kitakaze M; Hanai S; Nakajima T; Matsumoto K; Saito H; Goto Y; Kimura H; Katoh M; Sugai K; Minami N; Shirao K; Tamura T; Yamamoto N; Minami H; Ohtsu A; Yoshida T; Saijo N; Kitamura Y; Kamatani N; Ozawa S; Sawada J
Hum Mutat; 2004 Jan; 23(1):100. PubMed ID: 14695543
[TBL] [Abstract][Full Text] [Related]
38. Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes.
Makeeva O; Stepanov V; Puzyrev V; Goldstein DB; Grossman I
Pharmacogenomics; 2008 Jul; 9(7):847-68. PubMed ID: 18597650
[TBL] [Abstract][Full Text] [Related]
39. Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.
Perera MA; Thirumaran RK; Cox NJ; Hanauer S; Das S; Brimer-Cline C; Lamba V; Schuetz EG; Ratain MJ; Di Rienzo A
Pharmacogenomics J; 2009 Feb; 9(1):49-60. PubMed ID: 18825162
[TBL] [Abstract][Full Text] [Related]
40. Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs.
Berno G; Zaccarelli M; Gori C; Tempestilli M; Antinori A; Perno CF; Pucillo LP; D'Arrigo R
BMC Med Genet; 2014 Jul; 15():76. PubMed ID: 24986243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
